Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
基本信息
- 批准号:10333362
- 负责人:
- 金额:$ 42.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-13 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:Aconitic AcidAdaptive Immune SystemAffectAgonistAmericanAntimicrobial EffectAutomobile DrivingBiogenesisBiologyBurn TraumaCause of DeathCell RespirationCell physiologyCellsCessation of lifeCitric AcidCitric Acid CycleClinicalComplicationCritical IllnessDevelopmentFRAP1 geneFoundationsGenesGlycolysisGoalsHealthcare SystemsHospitalsImmuneImmune responseImmunologic MemoryImmunotherapyIncidenceIndividualInfectionInnate Immune ResponseInnate Immune SystemKnockout MiceKnowledgeLeukocytesLigandsLipid AMemoryMetabolicMetabolismMitochondriaModelingMolecularMyeloid CellsNosocomial InfectionsOrganismOxidative PhosphorylationPathway interactionsPatientsPeptidoglycanPhenotypePlayProductionPseudomonas aeruginosaPublic HealthResistanceResistance to infectionRoleSepsisSeveritiesSignal PathwaySignal TransductionStaphylococcus aureus infectionTLR4 geneTestingVaccinesVulnerable Populationsantimicrobialbasebeta-Glucansclinically relevantcognitive disabilitycytokinegene producthigh riskimmune resistanceimmune system functionin vivomacrophagemetabolic phenotypemicrobialmitochondrial metabolismmortalityorgan injurypathogenpathogen exposurepathogenic bacteriapathogenic fungusphysically handicappedpreventrecruitresponsesevere burnssurgical risk
项目摘要
Project Summary
Hospital-acquired infections are a major threat to public health, impacting 2 million patients and causing at
least 90,000 deaths annually. Sepsis is a common complication in patients with hospital-acquired infections
and the leading cause of death in non-cardiac intensive care units (ICU). Attempts at treating hospital-acquired
infections and sepsis have proven exceedingly difficult and patients that survive sepsis suffer long-term
physical and cognitive disabilities and a high 1-year mortality rate. Therefore, new strategies are needed to
decrease the burden of hospital-acquired infections and sepsis. Immunotherapy aimed at inducing
innate immune memory provides a way of achieving that goal. Recent studies show that innate immune
cells can retain memory of prior pathogen exposure and are primed to elicit a robust, broad-spectrum
antimicrobial response to subsequent infection. Treatment with TLR4 ligands, such as monophosphoryl lipid A
(MPLA), confers innate immune memory and resistance to a broad array of clinically important pathogens that
persists for more than 2 weeks. We propose that the appropriate application of TLR4 ligand-based
immunotherapy to induce innate immune memory has significant potential to reduce the burden of
hospital-acquired infections and sepsis. Macrophages are the foundation for development of innate
immune memory. Recent evidence indicates that remodeling of macrophage metabolism is central to the
induction of innate immune memory. Priming with TLR4 ligands induces a macrophage metabolic phenotype
characterized by increased glycolysis, oxidative metabolism and mitochondrial biogenesis with increased citric
acid cycle flux and associated increases in immunoresponsive gene 1 (Irg1) expression and itaconate
production. We hypothesize that macrophage metabolic remodeling and the increased production of
Irg1 and itaconate are essential to generating innate immune memory. To define the underlying biology,
we will: (1). Determine how Irg1 and itaconate drive TLR4 agonist-induced innate immune memory in
macrophages; (2). Define the importance of Irg1, itaconate and Nrf2 as regulators of the host response to
infection with common hospital-acquired pathogens after TLR4 agonist treatment in vivo.; (3). Define the
intracellular signaling pathways driving mitochondrial biogenesis, Irg1 expression and itaconate production in
TLR4 agonist-primed macrophages; (4). Determine the ability of diverse microbial ligands to induce
macrophage mitochondrial biogenesis, reprogram mitochondrial metabolism and function and induce innate
immune memory. We will test the hypothesis that, like TLR4 agonists, microbial ligands such as peptidoglycan,
CpG ODN and β-glucan, have the ability to reprogram macrophage metabolism and induce a memory
phenotype characterized by mitochondrial biogenesis, increased citric acid cycle flux, increased Irg1
expression and itaconate production with associated enhancement of antimicrobial functions.
项目摘要
医院获得性感染是对公共卫生的主要威胁,影响到200万患者,并导致
每年至少有9万人死亡。脓毒症是医院获得性感染患者的常见并发症。
也是非心脏重症监护病房(ICU)的主要死亡原因。治疗医院获得性疾病的尝试
感染和败血症已被证明是极其困难的,而存活下来的脓毒症患者将遭受长期的痛苦。
身体和认知残疾,一年死亡率高。因此,需要新的战略来
减少医院获得性感染和败血症的负担。免疫疗法旨在诱导
先天免疫记忆提供了一种实现这一目标的方法。最近的研究表明,先天免疫
细胞可以保留对先前病原体暴露的记忆,并被准备好引发一种强大的、广谱的
对后续感染的抗微生物反应。TLR4配体的治疗,如单磷酰脂A
(Mpla),赋予先天免疫记忆和对一系列临床重要病原体的抵抗力
持续两周以上。我们建议以TLR4为配体的适当应用
诱导先天免疫记忆的免疫疗法具有显著的潜力,可以减轻
医院获得性感染和败血症。巨噬细胞是先天发育的基础
免疫记忆。最近的证据表明,巨噬细胞代谢的重塑是
诱导先天免疫记忆。TLR4配体诱导巨噬细胞代谢表型
特点是随着柠檬酸的增加,糖酵解、氧化代谢和线粒体生物合成增加
酸循环通量和免疫反应基因1(IRG1)表达和衣康酸的相关增加
制作。我们假设巨噬细胞代谢重塑和增加的
IRG1和衣康酸是产生先天免疫记忆所必需的。为了定义潜在的生物学,
我们将:(1)。确定IRG1和衣康酸如何驱动TLR4激动剂诱导的先天性免疫记忆
巨噬细胞;确定IRG1、衣康酸和Nrf2作为宿主反应的调节因子的重要性
体内TLR4激动剂治疗后常见医院获得性病原菌感染情况。定义
线粒体生物发生、IRG1表达和衣康酸产生的细胞内信号通路
TLR4激动剂诱导的巨噬细胞;确定不同微生物配体诱导的能力
巨噬细胞线粒体生物发生,重新编程线粒体代谢和功能并诱导先天
免疫记忆。我们将检验这一假设,就像TLR4激动剂一样,微生物配体如肽聚糖,
CpG ODN和β-葡聚糖具有重新编程巨噬细胞代谢和诱导记忆的能力
以线粒体生物发生为特征的表型,柠檬酸循环通量增加,IRG1增加
表达和衣康酸生产与相关的抗菌功能的增强。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD R SHERWOOD其他文献
EDWARD R SHERWOOD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD R SHERWOOD', 18)}}的其他基金
Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
- 批准号:
10550138 - 财政年份:2020
- 资助金额:
$ 42.5万 - 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
- 批准号:
10296894 - 财政年份:2016
- 资助金额:
$ 42.5万 - 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
- 批准号:
10461115 - 财政年份:2016
- 资助金额:
$ 42.5万 - 项目类别:
Equipment supplement to "Training Innate Immunity: A new approach to the treatment of sepsis"
《训练先天免疫:治疗脓毒症的新方法》的设备补充
- 批准号:
10794766 - 财政年份:2016
- 资助金额:
$ 42.5万 - 项目类别:
Equipment Supplement request for a BD LSR Fortessa Flow Cytometer
BD LSR Fortessa 流式细胞仪的设备补充请求
- 批准号:
9275190 - 财政年份:2016
- 资助金额:
$ 42.5万 - 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
- 批准号:
10669060 - 财政年份:2016
- 资助金额:
$ 42.5万 - 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
- 批准号:
7256520 - 财政年份:2003
- 资助金额:
$ 42.5万 - 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
- 批准号:
7811704 - 财政年份:2003
- 资助金额:
$ 42.5万 - 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
- 批准号:
8578744 - 财政年份:2003
- 资助金额:
$ 42.5万 - 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
- 批准号:
8292209 - 财政年份:2003
- 资助金额:
$ 42.5万 - 项目类别:
相似海外基金
Single-cell analysis of adaptive immune system cells in IBD patients
IBD 患者适应性免疫系统细胞的单细胞分析
- 批准号:
22KJ2212 - 财政年份:2023
- 资助金额:
$ 42.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 42.5万 - 项目类别:
Elucidation of the adaptive immune system in teleost fish
阐明硬骨鱼的适应性免疫系统
- 批准号:
22K05824 - 财政年份:2022
- 资助金额:
$ 42.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10434937 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
Peripheral Adaptive Immune System Changes Associated with Alzhiemer's Disease
与阿尔茨海默病相关的外周适应性免疫系统变化
- 批准号:
10194864 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10302501 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10275426 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
CAREER: Emergence of Functional Organization in the Adaptive Immune System
职业:适应性免疫系统中功能组织的出现
- 批准号:
2045054 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
Continuing Grant
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10669709 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10467050 - 财政年份:2021
- 资助金额:
$ 42.5万 - 项目类别: